J Cardiovasc Ultrasound.  2008 Dec;16(4):130-132. 10.4250/jcu.2008.16.4.130.

Drug-Induced Dilated Cardiomyopathy Associated with Anagrelide

• Kim SY
• Kim JY
• Youn YJ
• Lee NS
• Ahn MS
• Lee KH
• Kim HY
• Choe KH

• KMID: 1486393
• DOI: http://doi.org/10.4250/jcu.2008.16.4.130

Abstract

Anagrelide is an effective drug for essential thrombocythaemia, and its adverse cardiovascular effects are relatively rarely reported. We experienced a 73 year-old man with essential thrombocythaemia developed anagrelide-induced dilated cardiomyopathy. After discontinuation of anagrelide, the patient's left ventricular systolic function was completely recovered.

Keyword

Anagrelide; Cardiomyopathy

MeSH Terms

Cardiomyopathies
Cardiomyopathy, Dilated
Quinazolines
Quinazolines

Figure

• 

  Fig. 1 Parasternal long axis views on ER visit due to dyspnea (A) and 3 month later after discharge (B). Figures shows decreased left ventricular end diastolic dimension (6.2→5.5 cm) and decreased left atrial dimension (4.9→3.9 cm).

Reference

1. Engel PJ, Johnson H, Baughman RP, Richards AI. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Ann Intern Med. 2005. 143:311–317.

2. James CW. Anagrelide-induced cardiomyopathy. Pharmacotherapy. 2000. 20:1224–1227.

3. Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica. 2004. 89:1394–1395.

4. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med. 2003. 114:51–55.

5. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992. 92:69–76.

6. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol. 1997. 34:51–54.